

**darunavir 75mg, 150mg, 300mg, 600mg film-coated tablets
(Prezista®) (No: 604/10)**

Tibotec, a subsidiary of Janssen-Cilag

Product Update

15 January 2010

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

darunavir (Prezista®) is accepted for use within NHS Scotland, co-administered with low dose ritonavir in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus (HIV-1) infection in highly pre-treated children and adolescents, from the age of 6 years and at least 20kg body weight, who have failed on more than one regimen containing a protease inhibitor (PI).

Darunavir is listed in the British National Formulary for Children for the treatment of HIV resistant to other protease inhibitors. The Scottish Medicines Consortium has previously accepted this product for use in this indication in adults.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

*This assessment is based on data submitted by the applicant company up to and including
18 November 2009*

**Chairman
Scottish Medicines Consortium**

Published 08 February 2010